- In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-‘749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-‘749 for ≥ 6 months met criteria for remission
asserted
fifth → receive → remission
Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-‘749 from existing regimens
-
asserted
analyses → provide → regimens
Ahead of the Q4 FDA anticipated approval decision, the growing body of science around TEV-‘749 demonstrates Teva’s commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise
PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) —
asserted
body → anticipate → franchise
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-‘749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies.
asserted
Pharmaceuticals → announce → strategies
The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-‘749 as a once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults.
asserted
data → highlight → adults
The findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
asserted
findings → present → Orleans
“These findings further validate the long-term clinical profile of TEV-‘749 and its potential to be a once-monthly subcutaneous injectable olanzapine treatment that can help support stabilization for people living with schizophrenia,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva.
asserted
Hughes → validate → Teva
“For those currently taking daily oral olanzapine and may be interested in switching to an LAI, these data suggest that TEV-‘749 can support long-term symptom control, helping to potentially fill an unmet need for this patient community.
uncertain
TEV-‘749 → take → community
Olanzapine is the most widely prescribed atypical antipsychotic for schizophrenia as a daily oral treatment.1 However, daily options may make it difficult to sustain long-term symptom improvement due to challenges with adherence, increasing the risk for instability and relapse.2
Long-Term Data Show High Stabilization and Low Rates of Relapse
In a post hoc analysis of the long-term treatment open-label period of the Phase 3 SOLARIS trial, more than half of all participants receiving TEV-‘749 achieved stabilization, more than one-fifth of long-term trial participants met criteria for remission (defined as maintaining a Positive and Negative Syndrome Scale [PANSS] item score of 3 or lower for at least six consecutive months across eight specific remission items), and few that had reached stabilization relapsed.
-
uncertain
that → prescribe → stabilization
Among 411 participants, 231 (56% [61%, 54%, and 54% with 318-, 425-, and 531-mg dose groups, respectively]) achieved stabilization
asserted
231 → achieve → stabilization
Among 231 participants who achieved stabilization, only 10 (4% [6%, 1%, and 5%]) experienced relapse
asserted
10 → achieve → relapse
Among 183 participants who were treated with TEV-‘749 for six or more months, 39 (21% [26%, 13%, and 26%]) achieved remission
asserted
39 → treat → remission
“These TEV-‘749 data are compelling because the vast majority of patients who start or respond well to olanzapine are treated with a daily oral pill of olanzapine,” said Christoph Correll, MD, Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.
asserted
Correll → start → Northwell
“We know that long-acting injectable treatment options may support stability and reduce risk of relapse, and TEV-‘749 has the potential to offer many of these individuals the efficacy of olanzapine in a once-monthly formulation.
uncertain
TEV-‘749 → know → formulation
Data Support Direct Switching from Daily Pills or Short-Acting Injections to Once-Monthly TEV-‘749
asserted
Data → support → TEV-‘749
In separate analyses simulating potential switching scenarios in the inpatient, initiation of TEV-‘749 one day after the last dose of oral or short-acting intramuscular olanzapine resulted in predictable olanzapine exposures that remained within established oral therapeutic ranges.
asserted
that → simulate → ranges
The findings offer clinical insights into how healthcare providers may switch patients to TEV-‘749 who are currently taking other olanzapine formulations.
uncertain
who → offer → formulations
Finally, an analysis of metabolic outcomes found that the metabolic profile of TEV-‘749 was consistent with daily oral olanzapine formulations, with no clear dose-dependent pattern observed.
asserted
profile → find → pattern
These data add to the broader safety and tolerability findings from the SOLARIS program.
asserted
data → add → program
Below is the full set of olanzapine LAI (TEV-‘749) posters being presented by Teva at Psych Congress 2026:
- (De novo) Durability of Response With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Schizophrenia: Post Hoc Analysis of the Phase 3 SOLARIS Trial
- (De novo) Population Pharmacokinetic Simulations of Inpatient Switching From Oral or Short-Acting Intramuscular Olanzapine to TV-44749
- (De novo) Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Efficacy Results From the Phase 3 SOLARIS Trial
- (De novo) Characterization of the Body Weight and Metabolic Profile of Subcutaneous Long-Acting Injectable Olanzapine (TV-44749): Results From the Phase 3 SOLARIS Trial
- (Modified encore) Joint Population Pharmacokinetic Model of Oral, Intramuscular, and Subcutaneous (TV-44749) Olanzapine to Support TV-44749 Dosing and Switching Strategies
TEV-‘749 is an investigational once-monthly subcutaneous LAI of the second-generation antipsychotic olanzapine.
asserted
TEV-‘749 → present → olanzapine
It is not approved by any regulatory authority for any use at this time.
asserted
It → approve → time
TEV-‘749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled steady, sustained release of olanzapine.
asserted
that → utilize → olanzapine
A PDUFA decision from the FDA is expected for TEV-‘749 in Q4 2026.
asserted
decision → expect → Q4
In the EU, the European Medicines Agency accepted the Marketing Authorization Application for TEV-‘749 in May 2026.
uncertain
Agency → accept → May
About Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS)
SOLARIS was a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-64 years) with schizophrenia.1
asserted
SOLARIS → control → schizophrenia.1
For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly olanzapine LAI (low, medium or high dose) or placebo in a 1:1:1:1 ratio.1
asserted
patients → randomize → ratio.1
For period two (next 48 weeks), patients who completed period one on placebo were re-
asserted
who → complete → placebo
randomized and equally allocated to one of the three olanzapine LAI treatment groups, while patients who completed period one on active olanzapine LAI remained on their established dose strength.1
asserted
who → randomize → strength.1
The end-of-treatment and follow-up visits were 4 and 8 weeks after administration of the last treatment dose, respectively.1
asserted
visits → follow → dose
The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of olanzapine LAI in adult patients with schizophrenia, as measured by PANSS.1
asserted
objective → evaluate → schizophrenia
A key secondary objective was to further evaluate the efficacy of olanzapine LAI based on additional parameters in adult patients with schizophrenia, as measured by CGI-S and PSP.1
asserted
objective → evaluate → S
A secondary objective of period two of the study was to evaluate the safety and tolerability of olanzapine LAI in adult patients with schizophrenia.1
About
asserted
objective → evaluate → schizophrenia.1
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.2
asserted
one → affect → ?
Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.2,3,4
uncertain
which → experience → delusions
Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 2.2 million people in the U.S. are currently diagnosed with the condition.3,4
asserted
people → develop → U.S.
Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.4
asserted
age → occur → 30s
The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.4 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.5,6,7
asserted
relapse → mark → function
Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.2,3,4,5,6,7
About
asserted
Patients → contribute → relapses
Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business.
asserted
Ltd. → transform → business
For over 120 years, Teva’s commitment to bettering health has never wavered.
asserted
commitment → better → health
…and 12 more, not listed.
The Aporia
